Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic.

Literature DB >> 17328233

Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic.

Abstract

Optimer Pharmaceuticals Inc, in collaboration with Par Pharmaceutical Companies Inc, is developing OPT-80, a narrow-spectrum macrocyclic antibiotic secreted by the actinomycete Dactylosporangium aurantiacum, for the potential treatment of Clostridium difficile-associated diarrhea (CDAD) and vancomycin-resistant Enterococcus infection. A phase IIb/III clinical trial of OPT-80 in patients with CDAD is underway.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2007 PMID： 17328233

Source DB: PubMed Journal: Curr Opin Investig Drugs ISSN： 1472-4472

Keyword Cloud
Cited

12 in total

1. In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp.

Authors: Douglas J Biedenbach; James E Ross; Shannon D Putnam; Ronald N Jones
Journal: Antimicrob Agents Chemother Date: 2010-03-22 Impact factor: 5.191

2. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses.

Authors: Y K Shue; P S Sears; S Shangle; R B Walsh; C Lee; S L Gorbach; F Okumu; R A Preston
Journal: Antimicrob Agents Chemother Date: 2008-02-11 Impact factor: 5.191

Review 3. Clinical update for the diagnosis and treatment of Clostridium difficile infection.

Authors: Edward C Oldfield; Edward C Oldfield; David A Johnson
Journal: World J Gastrointest Pharmacol Ther Date: 2014-02-06

Review 4. Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.

Authors: Kathleen Mullane
Journal: Ther Adv Chronic Dis Date: 2014-03 Impact factor: 5.091

Review 5. New target for inhibition of bacterial RNA polymerase: 'switch region'.

Authors: Aashish Srivastava; Meliza Talaue; Shuang Liu; David Degen; Richard Y Ebright; Elena Sineva; Anirban Chakraborty; Sergey Y Druzhinin; Sujoy Chatterjee; Jayanta Mukhopadhyay; Yon W Ebright; Alex Zozula; Juan Shen; Sonali Sengupta; Rui Rong Niedfeldt; Cai Xin; Takushi Kaneko; Herbert Irschik; Rolf Jansen; Stefano Donadio; Nancy Connell; Richard H Ebright
Journal: Curr Opin Microbiol Date: 2011-08-19 Impact factor: 7.934

6. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.

Authors: Derrick W Crook; A Sarah Walker; Yin Kean; Karl Weiss; Oliver A Cornely; Mark A Miller; Roberto Esposito; Thomas J Louie; Nicole E Stoesser; Bernadette C Young; Brian J Angus; Sherwood L Gorbach; Timothy E A Peto
Journal: Clin Infect Dis Date: 2012-08 Impact factor: 9.079

Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic.

1. In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp.

2. Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses.

Review 3. Clinical update for the diagnosis and treatment of Clostridium difficile infection.

Review 4. Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance.

Review 5. New target for inhibition of bacterial RNA polymerase: 'switch region'.

6. Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.

7. New advances in the treatment of Clostridium difficile infection (CDI).

8. Emerging therapies for Clostridium difficile infection - focus on fidaxomicin.

Review 9. A Review of Management of Clostridium difficile Infection: Primary and Recurrence.

Review 10. Fidaxomicin: A novel agent for the treatment of Clostridium difficile infection.